Why the study?
Prediabetes is considered an adverse cardiovascular risk factor after myocardial infarction, but ADA and WHO guidelines define prediabetes using different HbA1c ranges.
Does prediabetes defined by different HbA1c ranges predict in-hospital and one-year death in patients with STEMI?
Does prediabetes defined by different HbA1c ranges predict in-hospital and one-year death in patients with STEMI?
In patients with STEMI, prediabetes defined by different HbA1c ranges correlates with cardiovascular risk factors but is not significantly associated with increased in-hospital or one-year mortality compared to patients without diabetes.
Answers are grounded in this paper and cite their sources.
In STEMI, prediabetes by HbA1c should not yet alter acute risk stratification; leaves open whether tighter control improves outcomes in prospective trials.
Background: Prediabetes (preT2D) is considered a subtle adverse cardiovascular (CV) risk factor after acute myocardial infarction. Glycated hemoglobin (HbA1c) ranges to identify preT2D are different between ADA and WHO guidelines (5.7–6.4 vs. 6.0–6.4%, respectively). Aim: To evaluate the prognostic value of HbA1c different preT2D-ranges and their correlation with demographic, instrumental, and laboratory parameters in STEMI. Methods: A total of 1681 patients (mean age 67 ± 13 years; 1217 males) were enrolled. Admission HbA1c was used to identify patients with no-T2D (<5.7%), HbA1c 5.70–5.99%, and WHO-preT2D with HbA1c 6–6.49%, and T2D (HbA1c ≥ 6.5). Results: HbA1c 5.7–5.99, WHO-preT2D, and T2D progressively correlated with an increasing number of CV risk factors. However, only T2D, but not preT2D, was significantly associated with adverse prognosis (in-hospital and one-year death). Conclusions: PreT2D is correlated with CV risk factors, but not with adverse prognosis as compared to no-T2D. Nonetheless, routine HbA1c testing in the STEMI population and HbA1c-5.7–5.99 patient inclusion in the preT2D category may help to identify those who may benefit from intervention and lifestyle strategies to early prevent preT2D progression.
No takes yet. Share an insight, caveat, or question.
Chatzianagnostou et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: